Two analyses presented during the American Society of Clinical Oncology's 2016 Gastrointestinal Cancers Symposium evaluated the results of second-line treatment following treatment with a combination of Abraxane (paclitaxel protein-bound particles for injectable suspension; albumin-bound) and gemcitabine in first-line metastatic pancreatic cancer patients.
OBI Pharma Inc., announced topline results from a phase II/III study of OBI-822/821 (formerly OPT822/OPT821), which evaluated the clinical benefit and immunogenicity in patients with metastatic breast cancer. The study did not meet the primary efficacy endpoint of progression-free survival.
FDA approved Gazyva (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva alone as a new treatment for people with follicular lymphoma who did not respond to a Rituxan (rituximab)-containing regimen, or whose follicular lymphoma returned after such treatment.
Full results from a phase III study showed improved median overall survival in unresectable locally advanced liposarcomas and leiomyosarcomas in patients receiving Halaven (eribulin), compared to dacarbazine.
A phase III study of Blincyto met its primary endpoint of overall survival in patients with acute lymphoblastic leukemia following a prespecified interim analysis. The study was stopped early.
FDA granted accelerated approval to a combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
An analysis of a previously published phase III study prospectively validated five prognostic factors, referred to as the Moore criteria, used to identify a subset of patients with advanced cervical cancer that may not benefit from bevacizumab treatment.
A phase III study comparing Vectibix (panitumumab) and best supportive care met its primary endpoint, demonstrating a statistically significant improvement in overall survival in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer.
One of the largest randomized trials ever has concluded that ovarian cancer screening may reduce ovarian cancer mortality by an estimated 20 percent after follow up of up to 14 years, but researchers say longer follow-up is needed to determine the ultimate mortality reduction and if screening the general population is cost effective.
